These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34439854)

  • 21. Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    Chen T; Yu T; Zhuang S; Geng Y; Xue J; Wang J; Ai L; Chen B; Zhao Z; Li Y; Wang J; Liang H; Xu Y; Gu Y
    Br J Cancer; 2022 Sep; 127(5):916-926. PubMed ID: 35618786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
    Shao N; Shi Y; Yu L; Ye R; Shan Z; Zhang Z; Zhang Y; Lin Y
    Int J Biol Sci; 2019; 15(5):962-972. PubMed ID: 31182917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
    Zhang M; Liu G; Xue F; Edwards R; Sood AK; Zhang W; Yang D
    Gynecol Oncol; 2016 Apr; 141(1):57-64. PubMed ID: 27016230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 25. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
    Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
    Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TGFβ induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes.
    Liu L; Zhou W; Cheng CT; Ren X; Somlo G; Fong MY; Chin AR; Li H; Yu Y; Xu Y; O'Connor ST; O'Connor TR; Ann DK; Stark JM; Wang SE
    Mol Cancer Res; 2014 Nov; 12(11):1597-609. PubMed ID: 25103497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The development of PARP as a successful target for cancer therapy.
    Ferrara R; Simionato F; Ciccarese C; Grego E; Cingarlini S; Iacovelli R; Bria E; Tortora G; Melisi D
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):161-175. PubMed ID: 29260919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
    Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
    Misenko SM; Patel DS; Her J; Bunting SF
    Cell Cycle; 2018; 17(7):881-891. PubMed ID: 29620483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCAness revisited.
    Lord CJ; Ashworth A
    Nat Rev Cancer; 2016 Feb; 16(2):110-20. PubMed ID: 26775620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
    Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
    Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
    Ning J; Wakimoto H
    Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCAness: a deeper insight into basal-like breast tumors.
    De Summa S; Pinto R; Sambiasi D; Petriella D; Paradiso V; Paradiso A; Tommasi S
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii13-viii21. PubMed ID: 24131964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
    Incorvaia L; Perez A; Marchetti C; Brando C; Gristina V; Cancelliere D; Pivetti A; Contino S; Di Giovanni E; Barraco N; Bono M; Giurintano A; Bazan Russo TD; Gottardo A; Cutaia S; Pedone E; Peri M; Corsini LR; Fanale D; Galvano A; Scambia G; Badalamenti G; Russo A; Bazan V
    Cancer Treat Rev; 2023 Dec; 121():102650. PubMed ID: 37939446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olaparib for the treatment of breast cancer.
    Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precision Medicine in Castration-Resistant Prostate Cancer: Advances, Challenges, and the Landscape of PARPi Therapy-A Narrative Review.
    Dimitrov G; Mangaldzhiev R; Slavov C; Popov E
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.